DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/11/2026 has been entered.
Status of the claims
Applicant’s amendment filed 05/11/2026 is acknowledged and enter. In the amendment, claims 31 and 32 have been canceled and claims 33 and 34 are newly added. Thus, claims 1, 4-7, 10-13, 17-30 and 33-34 are pending. Claims 17-32 were previously withdrawn. See the office action of 01/25/2024 for the withdrawal of the claims 17-32 as being directed to non-elected invention. Therefore, claims 1, 4-7 and 10-13 and 33-34 are examined on merits in this office action.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1 and dependent claims 4-7, 10-13 and 33-34 thereon, are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The term “co-factor protein” has not been clearly defined or described in the specification and the specification does clearly describe any specific co-factor protein that enhances binding between the target of the drug and the receptor. Claim 1 recites “co-factor protein” and recites “the co-factor protein enhances binding between the target of the drug and the receptor” without clear description of the nature of the co-factor protein. The binding partner of the target as claimed encompasses various types of molecules that binds the target, the drug includes various types of distinct drugs including hormones, various types of small molecules, toxins and antibody as drugs (therapeutic drugs) and the target includes various types of molecules that binds the drug.
The fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the invention as now claimed. See, e.g., Vas-Cath, Inc., 935 F.2d at 1563-64, 19 USPQ2d at 1117.
To satisfy the written description requirement, MPEP §2163 states, in part “…a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention.” Moreover, the written description requirement for a genus may be satisfied through sufficient description of a representative number of species by “…disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between functional and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus.”
The claims are drawn to a method of identifying an anti-drug antibody (antibody against a drug) in a sample by a process of enhancing binding between the target and the binding partner of the target with a co-factor protein, specifically, with a receptor and a co-factor protein, to enhance binding between the target and binding partner of the target. The application discloses generic “co-factor” in figures 1 and 4-6 with no clear disclosure and nature/binding properties of the co-factor let alone a specific co-factor the enhances binding of a specific target of a drug and a specific binding partner. Throughout the specification, the only disclosure of “target receptor” and “protein” combination (cofactor-protein) could be found in paragraph [0068] wherein the paragraph recites “The soluble target receptor and co-factor proteins were purchased from Sigma (St Louis, MO)” without any description of the nature, properties or description of the target receptor and the co-factor protein. Paragraphs [0080] and [0081] describes some of the anti-target antibodies that are frequently used to mitigate target interference. Paragraph [0080] recites that “various combinations of these antibodies were also evaluated but they failed to sufficiently inhibit target interference in monkey serum samples”. Paragraph [0080] also discusses that among the anti-target antibodies screened, only one partially inhibit target-mediated false positive signal and two anti-target antibodies actually potentiated (increased) the target-mediated false-positive signal. The limited or no clear description in the specification and without clearly identifying or describing receptor and proteins (co-factor protein) combination that enhances binding of the receptor to the target of the drug, wherein the genus encompassed by “receptor for the target” and “protein” (i.e. co-factor protein) potentially incudes a vast number of different protein molecules, does not adequately describe the entire genus of receptor for the target and protein (i.e. co-factor protein) combination, for different types of drug targets, that enhances binding between the receptor and the target of the drug.
Fig. 4A of the specification shows incorporation of target receptor and co-factor to bridging ADA assay. Specification teaches different concentrations of co-factor (without clearly identifying the co-factor and the target receptor) were added to the solution containing target receptor for conducting bridging ADA. So both the receptor and co-factor are required in the assay but the specification does not clearly describe which proteins (i.e. co-factor proteins) are utilized for different types of receptors of the target. Specification teaches incorporation of both target receptor and co-factor to bridging ADA assay to improve ADA detection (paragraph [0083]), but however, specification does not provide a clear definition and clear guidance of target receptor in combination with co-factor that enhances binding of target and binding partner of the target.
“Possession may not be shown by merely describing how to obtain possession of members of the claimed genus or how to identify their common structural features.” Ex parte Kubin, 83 USPQ2d 1410, 1417 (Bd. Pat. App. & Int. 2007) citing University of Rochester, 358 F.3d at 927, 69 USPQ2d at 1895. Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 1116).
Further, for a broad generic claim, the specification must provide adequate written description to identify the genus of the claim. In Regents of the University of California v. Eli Lilly & Co., the court stated:
“A written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as by structure, formula, [or] chemical name,' of the claimed subject matter sufficient to distinguish it from other materials. Fiers, 984 F.2d at 1171, 25 USPQ2d at 1606; In re Smythe, 480 F.2d 1376, 1383, 178 USPQ 279, 284-85 (CCPA 1973) ("In other cases, particularly but not necessarily, chemical cases, where there is unpredictability in performance of certain species or sub combinations other than those specifically enumerated, one skilled in the art may be found not to have been placed in possession of a genus. . . ."). Regents of the University of California v. Eli Lilly & Co., 43 USPQ2d 1398.
The MPEP further states that if a biomolecule is described only by a functional characteristic, without any disclosed correlation between function and structure of the sequence, it is “not sufficient characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence.” MPEP 2163. The MPEP does state that for generic claim the genus can be adequately described if the disclosure presents a sufficient number of representative species that encompass the genus. MPEP 2163. If the genus has a substantial variance, the disclosure must describe a sufficient variety of species to reflect the variation within that genus. See MPEP 2163. Although the MPEP does not define what constitute a sufficient number of representatives, the Courts have indicated what do not constitute a representative number species to adequately describe a broad generic. In Gosteli, the Court determined that the disclosure of two chemical compounds within a subgenus did not describe that subgenus. In re Gosteli, 872 F.2d at 1012, 10 USPQ2d at 1618.
The court and the Board have repeatedly held (Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.,18 USPQ2d 1016 (CA FC, 1991); Fiers v. Revel, 25 USPQ2d 1601 (CA FC 1993); Fiddes v. Baird, 30 USPQ2d 1481 (BPAI 1993) and Regents of the Univ. Calif. v. Eli Lilly & Co., 43 USPQ2d 1398 (CA FC, 1997)) that an adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it, irrespective of the complexity or simplicity of the method; what is required is a description of the nucleic acid itself.
The specification does not provide an adequate written description of the genus of molecule encompassed by the “receptor of the target” and “protein”(i.e. co-factor protein) as encompassed in the claims, nor does the specification provide sufficient guidance that would allow one of skill in the art to readily identify the members of the claimed genus of “binding partner of a target” and its co-factor that enhances binding of the target and the binding partner of the target, without further experimentation. Thus, one of skill at the time of the invention could not have concluded that Applicant was in possession of the genus of molecules that is required to practice any of the claimed method.
Response to argument
Applicant's arguments and amendments filed 05/11/2026 have been fully considered and are persuasive to overcome the rejections under 35 USC 112(b) in view of the amendments. The 35 USC 103 rejection over Zhong in view of Summer has been withdrawn in view of Applicant’s incorporation of co-factor protein and for the recitation that the co-factor protein enhances binding between the target of the drug and the binding partner of the target. However, see the modified 35 USC 112 (a) rejection for lack of written description for the nature of various co-factor proteins that enhances binding between the various types of molecules as targets of the drugs and the various types of binding partners. The 35 USC 103 rejection will be re-instated if the co-factor protein and the recitation “the co-factor protein enhances binding between the target of the drug and the binding partner of the target” is removed from the claim. Regarding rejections under 35 USC 112(a), Applicant’s arguments have been rendered moot in view of the new grounds of rejections as described in this office action that are necessitated by Applicant’s amendments. Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAFIQUL HAQ whose telephone number is (571)272-6103. The examiner can normally be reached on Mon-Fri 8-4:30.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory S. Emch can be reached on 571-272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SHAFIQUL HAQ/Primary Examiner, Art Unit 1678
Prosecution Insights